In comparison to the monotherapy that reduced tumor burden without causing tumor eradication, treatment groups receiving CCL21-DC tumor lysate vaccine plus anti-PD-1 led to 80% tumor eradication (Table 1). The gene discussed is CCL21; the disease is neoplasm.